Recent studies suggest that depression may be a crucial risk factor for the development of
cognitive impairment and Alzheimer's disease (AD). In fact, there is a strong association
between late-life depression and AD. The age of AD onset has been shown to be accelerated in
patients with mild cognitive impairment (MCI) with a history of depression, and women appear to
be particularly more vulnerable to this condition. In addition, individuals with MCI who present
depressive symptoms have an elevated burden of amyloid-beta, the main toxic protein
associated with AD pathology, and a higher risk of developing AD compared to non-depressed
MCI patients. Although it has been described that some transgenic models of AD can develop
signs similar to depression in advanced stages, the induction of AD pathology due to a
depressive process has not been studied under experimental conditions to emulate late-life
depression as a risk factor for dementia. The objective of this study is to determine, by inducing
unpredictable mild chronic stress (CUMS) in tau transgenic P301S mice, whether depression is
a cause, rather than a consequence, of tau-associated pathology. The results of our study
indicate that the induction of CUMS in transgenic animals accelerates tau pathology, synaptic
impairment, elevates neuroinflammation, and triggers GABAergic alterations, in addition to
worsen clinical signs. The findings generated in this project could provide solid evidence of
depression as a risk factor for AD and other tauopathies.